Sacubitrilo / Valsartán: a jump of quality in the treatment of the heart inadequacy

Introduction: The advances in the prevention, diagnosis and treatment of the cardiovascular illnesses have been excellent, taking place significant reductions of the rates of mortality; it has not happened this way with the heart inadequacy; the high indexes of hospitalization, disability, morbilidad, mortality that takes place, took to the necessity of developing new fármacos, fruit of this the obtaining of Sacubitrilo/Valsartán, medication that inhibits system renina-angiotensina-aldosterona, was and it retards the degradation of the péptidos natriuréticos. The results of several studies took to that from the year 2021 were included in the basic pillars for the treatment of the inadequacy. Method: He/she was carried out a search in several bibliographical databases, revising the clinical studies published on the use of the medication. Results: The PARADIGM-HF was the first rehearsal that showed its benefits, with significant reduction of the mortality and the hospitalizations; other publications have confirmed their effectiveness, security, tolerance and improvement of the functional and renal capacity. Conclusions: The weight of the accumulated evidence, with the use of Sacubitrilo/Valsartán is incontrastable and its introduction in the clinical practice, he/she will go consolidating its indication in the treatment protocols that a revolutionary change will imply in the presage and with it the so yearned reduction of the mortality and the hospital entrance.